Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00196365 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
A Phase 3 study, sponsored by Duramed Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
NCT00196365: Completed Phase 3 study, sponsored by Duramed Research.
NCT00196365 is a Phase 3 study that has completed, run by Duramed Research. The registered enrollment target is 97 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00196365, a Phase 3 study, has completed, sponsored by Duramed Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary.
Interventions
- DRUG levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
- DRUG levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
What the finished NCT00196365 record still lists
NCT00196365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets is the first listed.
NCT00196365 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00196365 about?
NCT00196365 is a clinical study titled "A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain". This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9...
What is the current status of trial NCT00196365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2005-01. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00196365?
The interventions under investigation include: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets (DRUG), levonorgestrel/EE 0.15/0.03 mg tablets and placebo (DRUG).
Who is sponsoring clinical trial NCT00196365?
This trial is sponsored by Duramed Research, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00196365's enrollment target sits among peer trials
97 1718th of 2000 higher than 283 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia